GSK To Buy T Cell-engager For Multiple Myeloma From Chimagen Biosciences For Up To $750 Mln

Berenberg upgraded GSK to 'buy' with a £22 price target, citing a stronger drug pipeline and dealmaking. GSK shares rose 0.4% to £18.62. The broker noted GSK's 23% discount to peers is unjustified, with 10 of 11 Phase 3 assets sourced externally. Berenberg expects £39B in 2031 sales, above consensus, and sees near-term catalysts from upcoming regulatory decisions.

GSK (LSE/NYSE: GSK) will acquire a trispecific T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences, a privately held biotech firm. The asset, set to enter clinical trials in 2027, targets two tumor antigens and aims to improve efficacy and safety. The deal, valued at up to $750 million, aligns with GSK's oncology portfolio. Multiple myeloma is the third most common blood cancer globally, with 180,000 new cases annually.

London's FTSE 100 rose 0.4% on Monday, led by defensive sectors like healthcare and consumer staples. GSK gained 4.7% after positive drug trial results. Oil majors Shell and BP rose 1% each. Government bond yields hit multi-year highs. Investors await central bank decisions from the BoE and Fed this week.

GSK (NYSE:GSK) stock rose Monday after positive clinical trial results for two lung cancer treatments. Risvutatug rezetecan showed a 54% reduction in mortality risk in small cell lung cancer, while Jideytro achieved a 94% response rate in non-small cell lung cancer. The company plans to seek FDA approval for Jideytro this year. GSK shares were up 4.07% to $50.10 at the time of publication.

GSK's shares rose 3.83% to $49.97 after presenting positive lung cancer drug trial results at a conference. The trials showed strong results for Jideytro and Ris-Rez, with plans for U.S. regulatory approval. Analysts' reactions varied, with some raising price targets and others maintaining cautious ratings. GSK aims to expand its oncology pipeline as a key growth driver.

GSK's stock rose 3.4% to 1,830.5p after presenting positive clinical trial data for Jideytro and Ris-Rez at the 2026 World Conference on Lung Cancer. Jideytro, acquired via Nuvalent, showed a 94% response rate in ROS1-positive lung cancer patients. Ris-Rez, licensed from Hansoh Pharmaceutical, reduced death risk by 54% in relapsed small cell lung cancer. GSK plans to use the data for FDA applications, boosting investor confidence in its oncology pipeline.